US Medicaid drug bill "pay and chase" failing

12 August 2001

The "pay and chase" system of settling US Medicaid drug bills, underwhich the program pays the bill and then gets the money back from the private insurer which owes it, is failing, says a new report from the Office of the Inspector General of Health and Human Services.

The system was introduced as a seemingly more efficient way to collect money for prescription drugs but, out of $440 million owed in 32 US states in 1999, only $73 million was ever collected, says the study. It calls on the HHS to investigate whether states which do not have permission to use "pay and chase" are in fact doing so, and says that those which do use it should monitor the funds which they manage to recover. It also calls for legislation to give Medicaid up to three years to recover such money and to make clear that pharmacy benefit managers are third-party Medicaid payers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight